Cargando…
Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease
Pulmonary hypertension due to left heart disease (PH-LHD; Group 2), especially in the setting of heart failure with preserved ejection fraction (HFpEF), is the most frequent cause of PH. Despite its prevalence, no effective therapies for PH-LHD are available at present. This is largely due to the la...
Autores principales: | Todd, Noah, Lai, Yen-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575769/ https://www.ncbi.nlm.nih.gov/pubmed/33117832 http://dx.doi.org/10.3389/fmed.2020.570016 |
Ejemplares similares
-
Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease
por: Charalampopoulos, Athanasios, et al.
Publicado: (2018) -
Metformin in Pulmonary Hypertension in Left Heart Disease
por: Mulkareddy, Vinaya, et al.
Publicado: (2020) -
Pathogenesis of pulmonary hypertension caused by left heart disease
por: Xiao, Mingzhu, et al.
Publicado: (2023) -
Pulmonary hypertension due to left heart disease
por: Vachiéry, Jean-Luc, et al.
Publicado: (2019) -
An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
por: Santos-Gomes, Joana, et al.
Publicado: (2022)